News
-
-
-
-
-
COMMUNIQUÉ DE PRESSE
Board of Directors of Komax Holding AG nominates Andreas Häberli for election as Chairman at the 2025 Annual General Meeting
Komax Holding AG Board of Directors nominates Andreas Häberli as Chairman at 2025 Annual General Meeting. Beat Kälin steps down after 10 years as Chairman -
-
-
COMMUNIQUÉ DE PRESSE
Newron and EA Pharma (a subsidiary of Eisai Co., Ltd.) announce license agreement for evenamide in Japan and other Asian territories
Newron Pharmaceuticals S.p.A. and EA Pharma (a subsidiary of Eisai Co., Ltd.) have signed a license agreement for evenamide in Japan and other Asian territories, aiming to address unmet medical needs in patients with schizophrenia -
COMMUNIQUÉ DE PRESSE
Press Release: Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosis
FDA designates tolebrutinib as Breakthrough Therapy for non-relapsing SPMS based on positive HERCULES study results. Sanofi awaits regulatory review for this innovative medicine -
COMMUNIQUÉ DE PRESSE
Communiqué de presse : Le tolebrutinib obtient la désignation de « Médicament innovant » de la FDA pour le traitement de la sclérose en plaques secondairement progressive sans poussées
Le tolebrutinib reçoit la désignation 'Médicament innovant' de la FDA pour traiter la SEP-SP sans poussées, grâce aux résultats positifs de l'étude HERCULES. Sanofi prévoit de finaliser les soumissions réglementaires aux États-Unis et en Europe
